← back to search

Krishna R. Kalari

WinnMed · US
Area of research
Cancer Research · Genetics
Research interest
Research interests include Estrogen and related hormone effects, Cancer Genomics and Diagnostics, Bioinformatics and Genomic Networks, and Cancer, Lipids, and Metabolism.
h-index
47
citations
9,638
works
426
NIH funding
primary concept
Medicine
email

Recent publications

QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid-Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium.
2025cited by 4position: contributordoi
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer
npj Breast Cancer 2025cited by 1position: middledoi
Influence of gut microbiota on oral drug absorption and metabolism
2025cited by 1position: contributordoi
Supplementary File 3 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2025cited by 0position: contributordoi
Supplementary File 4 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2025cited by 0position: contributordoi
Supplementary File 1 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2025cited by 0position: contributordoi
Supplementary File 2 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2025cited by 0position: contributordoi
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networks.
2024cited by 7position: contributordoi
Data from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 3 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 1 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 1 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 2 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 4 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 2 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 4 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Supplementary File 3 from Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer
2024cited by 0position: contributordoi
Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer.
2023cited by 10position: contributordoi
Supplementary File 3 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2023cited by 0position: contributordoi
Supplementary Figure from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Supplementary Data from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Supplementary Figure from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Supplementary File 3 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2023cited by 0position: contributordoi
Supplementary Figure from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Supplementary Figure from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Data from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Supplementary File 2 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2023cited by 0position: contributordoi
Supplementary Figure from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
2023cited by 0position: contributordoi
Supplementary File 1 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2023cited by 0position: contributordoi
Supplementary File 4 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 47 papers (2022–2025)Richard Weinshilboum · Io Therapeutics (United States)41 papers (2022–2025)Liewei Wang · Tsinghua University41 papers (2022–2025) · 41 papers (2022–2025)Sihai Dave Zhao · Georgia Institute of Technology24 papers (2023–2025)Charles Blatti · National Center for Supercomputing Applications24 papers (2023–2025)Irene Marín-Goñi · Universidad de Navarra24 papers (2023–2025)Huanyao Gao · Nanjing Medical University24 papers (2023–2025)Zikun Chen · University of Illinois at Urbana-Champaign College of Engineering24 papers (2023–2025)Mikel Hernaez · Roche (France)24 papers (2023–2025)Jesús de la Fuente · Tecnalia24 papers (2023–2025)Scott M. Dehm · University of Minnesota18 papers (2022–2023)Alan H. Bryce · The University of Texas Southwestern Medical Center17 papers (2022–2023)Hugues Sicotte · University of Minnesota Rochester17 papers (2022–2023)David W. Hillman · Alliance Data (United States)17 papers (2022–2023)Sisi Qin · University of Chicago17 papers (2022–2023)Vipul Bhargava · Mayo Clinic17 papers (2022–2023) · 17 papers (2022–2023)Peter T. Vedell · Mayo Clinic17 papers (2022–2023)Rachel E. Carlson · Mayo Clinic17 papers (2022–2023)